These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 25358874)

  • 1. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
    Ye Z; Zhang L; Xu L; Shi W; Hu H; Shi X; Zhong W; Hou S; Yan H; Zhang B; Xia Y; Wang W; Feng Z; Wang L; Liang Y
    Nephrology (Carlton); 2014 Jan; 19(1):40-6. PubMed ID: 24191893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
    Wu J; Duan SW; Sun XF; Li WG; Wang YP; Liu WH; Zhang JR; Lun LD; Li XM; Zhou CH; Li JJ; Liu SW; Xie YS; Cai GY; Ma L; Huang W; Wu H; Jia Q; Chen XM
    Chin Med J (Engl); 2016 Aug; 129(16):1894-903. PubMed ID: 27503012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
    Min L; Wang Q; Cao L; Zhou W; Yuan J; Zhang M; Che X; Mou S; Fang W; Gu L; Zhu M; Wang L; Yu Z; Qian J; Ni Z
    Oncotarget; 2017 Jul; 8(29):48375-48384. PubMed ID: 28415636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
    Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI; Na HY; Moon JY; Han SW; Yang DH; Lee SH; Park HC; Choi HY; Lim SD; Kie JH; Lee YK; Shin SK
    Korean J Intern Med; 2016 Mar; 31(2):335-43. PubMed ID: 26874511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
    Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
    Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment of combination therapy using an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker in a patient with IgA nephropathy].
    Horino T; Ito H; Tanimoto N; Yoshida T; Sasaoka A; Chijiwa T; Hosokawa T; Hashimoto K
    Nihon Jinzo Gakkai Shi; 2003; 45(2):104-8. PubMed ID: 12703406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T; Najafi I; Salimi BH; Broomand B
    Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.
    Bilić M; Munjas-Samarin R; Ljubanović D; Horvatić I; Galesić K
    Coll Antropol; 2011 Dec; 35(4):1061-6. PubMed ID: 22397239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Serum IgA in Children with IgA Nephropathy, Severity of Kidney Biopsy Findings and Long-Term Outcomes.
    Mizerska-Wasiak M; Małdyk J; Pańczyk-Tomaszewska M; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Firszt-Adamczyk A; Stankiewicz R; Bieniaś B; Zajączkowska M; Gadomska-Prokop K; Grenda R; Miklaszewska M; Pietrzyk J; Pukajło-Marczyk ; Zwolińska D; Szczepańska M; Demkow U; Roszkowska-Blaim M
    Adv Exp Med Biol; 2015; 873():79-86. PubMed ID: 26269025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy.
    Lou T; Wang C; Chen Z; Shi C; Tang H; Liu X; Yin P; Yu X
    Nephrology (Carlton); 2006 Apr; 11(2):113-6. PubMed ID: 16669971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
    Bazzi C; Rizza V; Casellato D; Stivali G; Rachele G; Napodano P; Olivieri G; Gallieni M; D'Amico G
    J Nephrol; 2012; 25(5):810-8. PubMed ID: 22252844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH; Lee JE; Park JH; Lim S; Jang HR; Kwon GY; Huh W; Jung SH; Kim YG; Oh HY; Kim DJ
    Ann Med; 2016; 48(3):171-81. PubMed ID: 27031662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.